https://www.selleckchem.com/products/cx-5461.html
OBJECTIVE Recent studies suggest that the P2Y12 receptor of vascular smooth muscle cells in atherosclerotic plaques aggravates atherosclerosis, and P2Y12 receptor inhibitors such as CDL (clopidogrel) may effectively treat atherosclerosis. It is imperative to identify an effective biomarker for reflecting the P2Y12 receptor expression on vascular smooth muscle cells in plaques. Approach and Results We found that there was a positive correlation between the level of circulating sLRP1 (soluble low-density lipoprotein receptor-related prote
Aimer
Commentaire
Partagez
